NAS:PIRS (USA) Also Trade In: Germany

Pieris Pharmaceuticals Inc $ 2.95 -0.04 (-1.34%)

Volume:
568,422
Avg Vol (1m):
519,296
Market Cap $:
154.58 Mil
Enterprise Value $:
93.25 Mil
P/E (TTM):
0.00
P/B:
3.31
Warning! GuruFocus has detected 3 Severe warning signs with PIRS. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Pieris Pharmaceuticals Inc () from 2014 to Sep 19 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Pieris Pharmaceuticals stock (PIRS) PE ratio as of Sep 19 2020 is 0. More Details

Pieris Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Pieris Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1296
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Pieris Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-09-190.0 2020-07-200.0
2020-09-180.0 2020-07-170.0
2020-09-170.0 2020-07-160.0
2020-09-160.0 2020-07-150.0
2020-09-150.0 2020-07-140.0
2020-09-140.0 2020-07-130.0
2020-09-110.0 2020-07-100.0
2020-09-100.0 2020-07-090.0
2020-09-090.0 2020-07-080.0
2020-09-080.0 2020-07-070.0
2020-09-070.0 2020-07-060.0
2020-09-040.0 2020-07-030.0
2020-09-030.0 2020-07-020.0
2020-09-020.0 2020-07-010.0
2020-09-010.0 2020-06-300.0
2020-08-310.0 2020-06-290.0
2020-08-280.0 2020-06-260.0
2020-08-270.0 2020-06-250.0
2020-08-260.0 2020-06-240.0
2020-08-250.0 2020-06-230.0
2020-08-240.0 2020-06-220.0
2020-08-210.0 2020-06-190.0
2020-08-200.0 2020-06-180.0
2020-08-190.0 2020-06-170.0
2020-08-180.0 2020-06-160.0
2020-08-170.0 2020-06-150.0
2020-08-140.0 2020-06-120.0
2020-08-130.0 2020-06-110.0
2020-08-120.0 2020-06-100.0
2020-08-110.0 2020-06-090.0
2020-08-100.0 2020-06-080.0
2020-08-070.0 2020-06-050.0
2020-08-060.0 2020-06-040.0
2020-08-050.0 2020-06-030.0
2020-08-040.0 2020-06-020.0
2020-08-030.0 2020-06-010.0
2020-07-310.0 2020-05-290.0
2020-07-300.0 2020-05-280.0
2020-07-290.0 2020-05-270.0
2020-07-280.0 2020-05-260.0
2020-07-270.0 2020-05-250.0
2020-07-240.0 2020-05-220.0
2020-07-230.0 2020-05-210.0
2020-07-220.0 2020-05-200.0
2020-07-210.0 2020-05-190.0

Pieris Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries PI6.Germany PIRS.USA
Address 255 State Street, 9th Floor, Boston, MA, USA, 02109
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.